Safety and tolerability of astegolimab, an anti-ST2 monoclonal antibody: a narrative review
Abstract Chronic inflammation is an underlying feature of respiratory diseases such as chronic obstructive pulmonary disease (COPD). Novel therapies that target the inflammatory mechanisms driving acute exacerbations of COPD are required. The ST2 receptor, which binds the alarmin interleukin (IL)-33...
Gorde:
| Egile Nagusiak: | , , , , , , , , , |
|---|---|
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
BMC
2025-10-01
|
| Saila: | Respiratory Research |
| Gaiak: | |
| Sarrera elektronikoa: | https://doi.org/10.1186/s12931-025-03360-0 |
| Etiketak: |
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|